Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Carcinoma, Non-Small-Cell Lung 13Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Hodgkin Disease 11Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Lymphocytic, Chronic, B-Cell 7Burkitt Lymphoma 7Breast Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Recurrence 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Blast Crisis 6Sezary Syndrome 5Prostatic Neoplasms 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma, B-Cell, Marginal Zone 5Brain Neoplasms 5

Interventions

Trastuzumab 8Paclitaxel 7Taxes 6Lapatinib 6Docetaxel 5veliparib 3Tamoxifen 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3sargramostim 2liposomal doxorubicin 2ixabepilone 2cediranib 2Vorinostat 2Vinorelbine 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Mifepristone 2MK 2206 2Interleukin-12 Subunit p35 2Interleukin-12 2Granulocyte-Macrophage Colony-Stimulating Factor 2Goserelin 2Gemcitabine 2Filgrastim 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms, Male × Vorinostat × Clear all
NCT01084057 2019-11-05

Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer

City of Hope Medical Center

Phase 1 Completed
56 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00045006 2013-05-30

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Neoplasms, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡